Want to see TSE:SVA full AI Analyst Report?
Top Page
Sernova
(TSX:SVA)
Select Model
Select Model
Rating:49Neutral
Price Target:
C$0.13
▼(-10.67% Downside)
Action:Reiterated
Date:06/18/26
The score is held down primarily by weak financial fundamentals (no revenue, ongoing cash burn, and especially negative equity/shrinking assets that increase funding risk). Technicals are moderately supportive with the price above key moving averages, but valuation remains unattractive/less assessable due to losses and no dividend.
Positive Factors
Proprietary platform advantage
Sernova's Cell Pouch System is a platform technology that creates a vascularized environment for therapeutic cells, supporting long-term cell function. A durable platform can address multiple chronic indications, create regulatory and technical barriers to entry, and support lifecycle clinical development.
Negative Factors
Deteriorated balance sheet / negative equity
Negative shareholders' equity is a material, lasting weakness that limits financial flexibility, raises insolvency and covenant risk, and makes traditional leverage metrics less meaningful. Over the coming months it increases the urgency to secure financing or strategic partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary platform advantage
Sernova's Cell Pouch System is a platform technology that creates a vascularized environment for therapeutic cells, supporting long-term cell function. A durable platform can address multiple chronic indications, create regulatory and technical barriers to entry, and support lifecycle clinical development.
Read all positive factors
Sernova (SVA) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$52.87M
Dividend YieldN/A
Average Volume (3M)125.66K
Price to Earnings (P/E)―
Beta (1Y)-0.24
Revenue GrowthN/A
EPS Growth49.13%
CountryCA
Employees17
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.03
Shares Outstanding377,642,520
10 Day Avg. Volume126,270
30 Day Avg. Volume125,661
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)-1.96
Price to Sales (P/S)0.00
P/FCF Ratio-4.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)C$300.50K
Sernova Business Overview & Revenue Model
Company Description
Sernova Corp. is a Canadian clinical-stage enterprise specializing in the development and commercialization of groundbreaking regenerative medicine therapies. Its core endeavors revolve around its proprietary Cell Pouch system and associated techn...
How the Company Makes Money
null...
Sernova Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -256.13K | -342.59K | -540.28K | -445.55K | -440.00K | -267.20K |
| EBITDA | -10.22M | -14.74M | -31.25M | -40.19M | -24.54M | -6.60M |
| Net Income | -11.83M | -15.74M | -32.19M | -39.00M | -24.54M | -7.02M |
Balance Sheet | ||||||
| Total Assets | 1.53M | 764.23K | 7.53M | 22.11M | 52.48M | 29.82M |
| Cash, Cash Equivalents and Short-Term Investments | 1.05M | 265.00K | 6.01M | 19.81M | 49.78M | 27.87M |
| Total Debt | 2.45M | 17.28M | 569.94K | 136.12K | 275.98K | 393.35K |
| Total Liabilities | 11.17M | 25.84M | 20.48M | 9.59M | 4.88M | 1.75M |
| Stockholders Equity | -9.64M | -25.08M | -12.96M | 12.51M | 47.61M | 28.07M |
Cash Flow | ||||||
| Free Cash Flow | -5.50M | -10.91M | -18.90M | -30.44M | -14.75M | -6.86M |
| Operating Cash Flow | -5.50M | -10.91M | -18.90M | -30.34M | -14.42M | -6.84M |
| Investing Cash Flow | 24.96K | 24.96K | 11.12M | 34.78M | -46.34M | -228.78K |
| Financing Cash Flow | 4.53M | 5.14M | 5.07M | 503.46K | 36.66M | 31.00M |
Sernova Technical Analysis
Negative
0.15
Price Trends
0.16
Negative
0.16
Negative
0.16
Negative
Market Momentum
>-0.01
Positive
44.39
Neutral
40.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:SVA, the sentiment is Negative. The current price of 0.15 is below the 20-day moving average (MA) of 0.15, below the 50-day MA of 0.16, and below the 200-day MA of 0.16, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.39 is Neutral, neither overbought nor oversold. The STOCH value of 40.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:SVA.
Sernova Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | C$61.04M | 37.02 | 3.31% | ― | -3.44% | -57.64% | |
53 Neutral | C$40.56M | -7.20 | -8.01% | ― | -34.81% | -453.45% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | C$52.87M | -3.85 | ― | ― | ― | 49.13% | |
42 Neutral | C$49.12M | -13.73 | ― | ― | -31.89% | 21.88% | |
41 Neutral | C$37.89M | -3.94 | ― | ― | ― | -40.15% |
* Healthcare Sector Average
TSE:SVA
Sernova
0.14
>-0.01
-6.90%
TSE:COV
Covalon Technologies
2.10
-0.18
-7.89%
TSE:MBX
Microbix Biosystms
0.30
<0.01
1.69%
TSE:MIR
Medmira
0.07
>-0.01
-6.67%
TSE:NRX
NurExone Biologic
0.55
-0.16
-22.54%
TSE:DTC
Defence Therapeutics
0.44
-0.29
-39.73%
Sernova Corporate Events
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and FinancingShareholder Meetings
Sernova Shareholders Approve Debt-Reducing Issuances and Re-elect Board at 2026 AGM
Positive
Apr 9, 2026
Sernova Biotherapeutics reported that all management proposals were approved at its April 8, 2026 annual general meeting, with 27.31% of outstanding shares represented and the full slate of directors re-elected for another year. Shareholders also ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.